Ratio Analysis: Unpacking Lyell Immunopharma Inc (LYEL)’s Price-to-Cash and Price-to-Free Cash Flow

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

After finishing at $2.54 in the prior trading day, Lyell Immunopharma Inc (NASDAQ: LYEL) closed at $2.50, down -1.57%. In other words, the price has decreased by -$1.57 from its previous closing price. On the day, 0.84 million shares were traded. LYEL stock price reached its highest trading level at $2.58 during the session, while it also had its lowest trading level at $2.47.


Our goal is to gain a better understanding of LYEL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.51 and its Current Ratio is at 16.51. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on August 28, 2023, Downgraded its rating to Neutral and sets its target price to $5 from $15 previously.

On November 14, 2022, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $15 to $7.

Goldman Downgraded its Buy to Neutral on November 11, 2022, whereas the target price for the stock was revised from $13 to $7.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 ’23 when Klausner Richard sold 58,020 shares for $2.28 per share. The transaction valued at 132,286 led to the insider holds 930,880 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 637347520 and an Enterprise Value of 183071616. For the stock, the TTM Price-to-Sale (P/S) ratio is 9105.00 while its Price-to-Book (P/B) ratio in mrq is 1.06. Its current Enterprise Value per Revenue stands at 2692.23 whereas that against EBITDA is -0.839.

Stock Price History:

The Beta on a monthly basis for LYEL is -0.49, which has changed by -0.026819944 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, LYEL has reached a high of $3.97, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is 6.76%, while the 200-Day Moving Average is calculated to be 20.87%.

Shares Statistics:

The stock has traded on average 906.41K shares per day over the past 3-months and 647550 shares per day over the last 10 days, according to various share statistics. A total of 253.96M shares are outstanding, with a floating share count of 118.13M. Insiders hold about 53.66% of the company’s shares, while institutions hold 27.67% stake in the company. Shares short for LYEL as of 1713139200 were 18226808 with a Short Ratio of 20.11, compared to 1710460800 on 10375548. Therefore, it implies a Short% of Shares Outstanding of 18226808 and a Short% of Float of 10.17.

Earnings Estimates

Lyell Immunopharma Inc (LYEL) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.22, while EPS last year was -$0.26. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.19 and low estimates of -$0.22.

Analysts are recommending an EPS of between -$0.74 and -$0.9 for the fiscal current year, implying an average EPS of -$0.84. EPS for the following year is -$0.85, with 2.0 analysts recommending between -$0.85 and -$0.85.

Most Popular

[the_ad id="945"]